ChAdOx1.tHIVconsv1
Phase 2Biologic
ChAdOx1.tHIVconsv1 is one of 36 biologic programs targeting HIV. It is currently in Phase 2.
1
Indications
5
Total Trials
3
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
57 competitors in HIV
#DrugCompanyPhaseTrials
1Cabenuva
GSKApproved
Pifeltro
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Tivicay
GSKPhase 3
Epivir
GGlaxo Dba Glaxosmithkline
Phase 3
Sunlenca
GileadPhase 3
Biktarvy
GileadPhase 3
Emtriva
GileadPhase 3
Vemlidy
GileadPhase 3
Priftin
SanofiPhase 2
Lamprene
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Immunogenicity3 trials
Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1
Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT06071767·36 enrolled
Vaccination1 trial
RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV
Recruiting·HHenry M. Jackson Foundation for the Advancement of Military Medicine·Phase 1·NCT06484335·48 enrolled
HIV1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ChAdOx1.tHIVconsv1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Oxford